Volume 2, 2012
 
 
Archive
 
+ Volume 2 2012
Issue 1
+ Volume 1 2011
 
 
Insight Bioinformatics>>  Volume 2 Issue 1, 2012
Download  |  PDF  

In silico and Wet Lab Analysis of Two Genes Polymorphism Which Candidate for a Methicillin-resistant Staphylococcus aureus Vaccine
Hamideh Rouhani Nejad , Jalil Fallah Mehrabadi , Mohammad Reza Pourmand and Mohammad Reza Zolfaghari
 
 
    How to Cite:
Hamideh Rouhani Nejad, Jalil Fallah Mehrabadi, Mohammad Reza Pourmand and Mohammad Reza Zolfaghari , 2012. In silico and Wet Lab Analysis of Two Genes Polymorphism Which Candidate for a Methicillin-resistant Staphylococcus aureus Vaccine. Insight Bioinformatics, 2: 9-13
DOI: 10.5567/BIOINFO-IK.2012.9.13
 


INTRODUCTION
Staphylococcus aureus is a bacterium that contributes to diseases including endocarditis, pyogenic infections and meningitis. While these diseases can be treated with antibiotics, the bacteria can quickly develop resistance (Shehata, 2008).

A major cause of nosocomial infections is methicillin-resistant S. aureus (MRSA) which can be readily transferred between patients in hospitals (Muder et al., 1991; Yang et al., 2006). Mupirocin is a treatment option with a decreased risk of surgery and carriage. However, Mupirocin resistance was first reported in 1987 in the U.K. (Rahman et al., 1987; Yang et al., 2006) and has since been reported in other countries (Gales et al., 2004; Schmitz et al., 1998; Yang et al., 2006). Therefore, the prevalence of MRSA is a major concern (Walker et al., 2003). S. aureus strains that are resistant to penicillin, methicillin and/or vancomycin have been reported by Centers for Disease Control and Prevention (2002). Vancomycin resistance was first reported in Japan (Hiramatsu et al., 1997) and its appearance in the U.S in 2002 raised concern (Centers for Disease Control and Prevention, 2004; Chang et al., 2003).

Specific antibodies and vaccines can prevent infectious diseases (Josephson et al., 2001; McKenney et al., 1999). Recently, candidate proteins for a staphylococcal vaccine have been identified that stimulate the immune system and cause an antibody response (Burine et al., 2000; Vytvytska et al., 2002). Polysaccharides and DNA in vaccines can prevent infection (Foster, 1991). Sixty surface and secretory proteins have been proposed for an immunogenic vaccine (Etz et al., 2002).

The Sca family contains nine proteins with conserved C-terminal domains of 40-60% homology (Pourmand and Foster, 2006). In this study, the Sca family genes saCOL2291 and saCOL2581 which encode the secretory antigens ScaC and ScaD, respectively, were evaluated for Single Nucleotide Polymorphisms (SNPs). These genes are candidates for a universal staphylococcal vaccine because they are present in most staphylococcal isolates. The purpose of our study was to detect variation in the saCOL2291 and saCOL2581 gene sequences and determine whether they are appropriate candidates for a universal staphylococcal vaccine.


MATERIALS AND METHODS
Bacterial strains: Thirty clinical S. aureus strains were collected from hospital patients in cities of IRAN from mucus, urine, wounds and CSF. Coagulase, DNase and catalase tests were performed to confirm that the isolates were S. aureus.

DNA extraction: All isolates were cultured at 37°C for 16 h in LB broth and genomic DNA was extracted using the Bioneer Kit (South Korea) according to manufacturer’s instructions.

Amplification of saCOL2291 and saCOL2581 and SNP detection: Molecular biology materials were obtained from Fermentas. Pfu DNA polymerase, a high fidelity enzyme, was used for PCR. Primers for the saCOL2291 (HM565739) and saCOL2581 (HQ179767) genes (Table 1) were designed based on the COL strain nucleotide sequences available from NCBI (www.ncbi.nlm.nih.gov/ nucleotide). The thermal cycling program consisted of an initial denaturation at 94°C for 4 min, 35 cycles of 94°C for 1 min, 62.7°C for 1 min and 72°C for 1 min and a final extension of 72°C for 5 min. The amplicons were sequenced (Macrogene Company, South Korea) and aligned with the COL strain nucleotide sequence using BLAST (www.ncbi.nlm.nih.gov/Blast). A multiple alignment of the thirty amplicon sequences was created with MEGA4 software. All nucleotide sequences were analyzed with Gene Runner software to deduce the amino acid sequences and multiple alignments were created.

Multiple alignment of submitted saCOL2291 and saCOL2581 genes: For assessing of gene polymorphism, all of submitted whole genome sequences of Staphylococcus species in Genome project database of NCBI were selected. They were 29 but 23 of them harbor saCOL2291 gene sequences with following accession numbers: CP002643.1, CP002453.1, FR714927.1, CP001844.2, CP002114.2, CP002120.1, CP001996.1, AM990992.1, FN433596.1, CP001781.1, CP000730.1, AP009324.1, AP009351.1, CP000736.1, CP000703.1, BA000017.4, CP000046.1, CP000253.1, CP000255.1, BX571857.1, BA000018.3, BA000033.2, BX571856.1.

At the same time, 26 Staphylococcus species contain saCOL2581 gene sequence with these accession numbers: CP002643.1, FR714927.1, CP002110.1, CP001844.2, CP002114.2, CP002120.1, CP001996.1, AM990992.1, FN433596.1, CP001781.1, CP000730.1, AP009324.1, AP009351.1, CP000736.1, CP000703.1, BA000017.4, CP000046.1, CP000253.1, CP000255.1, AC074026.14, X97985.1, BX571857.1, BA000018.3, BA000033.2, BX571856.1. Multiple alignment of selected sequences was performed by Mega4 software and all mutations at amino acid level was analyzed. Among 23 selected sequences of saCOL2291 and 26 saCOL2581 genes, 2 and 5 sequences,respectively, had nucleotides insertion which interrupt multiple alignment analysis. So, these sequences were omitted and remaining sequences were aligned.

Amplification of the saCOL2291 and saCOL2581 genes: The genomic DNA of thirty S. aureus clinical isolates was used as a template to PCR-amplify the saCOL2291 and saCOL2581 genes. The nucleotide sequences of saCOL2291 and saCOL2581 were obtained, aligned and compared with their COL strain counterparts. Alignments of each saCOL2291 or saCOL2581 sequence with the appropriate reference sequence revealed average homologies of 98.3 and 97.86%, respectively (results not shown). The C-terminal domains of these genes were conserved. The ScaC and ScaD amino acid sequences were analyzed to detect silent changes, transitions and transversions. The variation in the samples indicated that the tested strains were unrelated.


RESULTS
Gene polymorphisms in saCOL2291: In the S. aureus COL strain, the ssaA2 gene (804 bp) of the saCOL2291 locus encodes the staphylococcal secretory antigen ssaA2 (267 aa) with a 1 to 27 aa signal peptide at the N-terminal domain.

Table 1: Primer sequences used to amplify the saCOL2291 and saCOL2581 genes

The mutations listed in Table 2 is based on the multiple alignment of the nucleotide sequences.

An average of 1.6 transition mutations were detected in each sample while an average of 1.3 transversion mutations were detected. Many mutations affected the amino acid sequence; some replaced residues with amino acids of the same family while others altered the native amino acid to one from a different family. Mutations were detected in the N-terminal domains but the C-terminal domains were conserved.

Gene polymorphisms in saCOL2581: The S. aureus COL strain ssaA1 gene (768 bp) of the saCOL2581 locus encodes the staphylococcal secretory antigen ssaA1 (255 aa).

Table 2: Mutations in the ScaC and ScaD proteins
Brackets values are the number of isolates with that mutation. Parenthesis values are the amino acid position. *A histidine residue was deleted in 3 isolates but did not affect the reading frame of the amino acid sequence. # Tyrosine and asparagine or ^ alanine and tyrosine amino acids were inserted but did not change the frame. The rates of the analyzed mutations were up to 5 per sequence, excluding deletions and insertions

Table 3: Some mutation of saCOL2291 and saCOL2581 genes in NCBI
Brackets indicate the number of isolates with that mutation. The numbers in parenthesis indicate the amino acid position. *showed, this mutation is occur the same position as clinical isolates

The signal peptide at the N-terminal domain is composed of residues 1 to 26. Polymorphisms based on the multiple alignments of nucleotides and amino acids are listed in Table 2.

Transitions and transversions were detected at frequencies of 3.4 and 0.7 per sequence, respectively. Transitions were detected most frequently. While several mutations changed residues to an amino acid with similar properties, many produced changes resulting in the replacement of an amino acid with one from a different family.

Study based on bioinformatics method: Multiple alignment of protein sequences was presenting some mutations among sequences which downloaded from GenBank (Fig. 1). These mutations were listed in Table 3.


DISCUSSION
In the 21st century, the rapid acquisition of antimicrobial resistance in S. aureus is a major concern. Previously, resistance to methicillin and penicillin was detected; and recently, resistance to linezolid and other antibiotics has increased in frequency (Anderegg et al., 2005).

Thus, it is critical to identify resistance mechanisms and design new vaccines to prevent staphylococcal infections. One such vaccine containing conjugated polysaccharide capsule reduced infection in 56% of hemodialysis patients in a 10-month period (Shinefield et al., 2002). Another staphylococcal vaccine using the penicillin binding protein 2a (PBP2a) was used against MRSA strains and reduced the number of S. aureus cells in kidneys compared with non-immunized patients but the results were not promising (Senna et al., 2003).

Fig. 1: Multiple protein alignment of ScaC protein, C-terminal domain

The ScaC and ScaD proteins have been used as immunogens in a mouse model. These proteins induced a humoral immune response and the production of specific antibodies, indicating that these proteins are indeed immunogens (Dryla et al., 2005).

Gill et al. (2005) sequenced the whole genome of the S. aureus COL strain (Gill et al., 2005). In our study, the saCOL2291 and saCOL2581 genes of the COL strain were used as reference sequences and aligned with the corresponding genes of clinical isolates.

As a result of whole genome sequencing, sixty important surface and secretory proteins were identified as new immunogens in S. aureus using bacterial display methods (Etz et al., 2002). Pourmand detected S. aureus Sca family proteins using bioinformatics methods and designated this family as staphylococcal conserved antigen (Sca). Most of these genes are conserved in the C-terminal domain and are novel vaccine candidates (Foster, 1991; Pourmand and Foster, 2006). We investigated this hypothesis in clinical isolates.

To identify SNPs in the saCOL2291 and saCOL2581 genes, Pfu DNA polymerase which has a proofreading function, was used. SNPs were detected in all isolates. Some SNPs altered the amino acid sequences and the resulting functional effects must be evaluated. The C-terminal domains of these genes in the S. aureus isolates investigated in this study were conserved and thus are good vaccine candidates.

This study was explained most of submitted whole genome sequences of Staphylococcus species, contain saCOL2291 and saCOL2581 genes. Moreover, these genes contain point mutation just like saCOL2291 and saCOL2581 genes of clinical isolates in our survey. Alignment analysis of submitted sequences clarified conservation in these genes at C and N-terminal domain but the C-terminal domain is more conserve than N-terminal.

The submitted saCOL2291 and saCOL2581 genes at GenBank are from different area of the world. In bioinformatics based analysis, all sequences were conserved with some point mutations.

One of the most important properties of a protein candidate for designing an universal vaccine is sequence conservation. So, our data confirmed the conservation of C-terminal domains of these genes and we suggest to using C-terminal domain for designing a new candidate vaccine against methicillin-resistant S. aureus.


REFERENCES

Anderegg, T.R., H.S. Sader, T.R. Fritsche, J.E. Ross and R.N. Jones, 2005. Trends in linezolid susceptibility patterns: Report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) program. Int. J. Antimicrob. Agents, 26: 13-21

Burine, J.P., R.C. Matthews, T. Carter, E. Beaulieu, M. Donohoe and C. Chapman, 2000. Identification of an immunodominant ABC transporter in methicillin resistant Staphylococcus aureus infection. Infect. Immun., 68: 3200-3209

Centers for Disease Control and Prevention, 2002. Staphylococcus aureus resistant to vancomycin United States. Morb. Mortal. Weekly Rep., 51: 565-567

Centers for Disease Control and Prevention, 2004. Vancomycin-resistant Staphylococcus aureus New York. Morb. Mortal. Weekly. Rep., 53: 322-323

Chang, S., D.M. Sievert, J.C. Hageman, M.L. Boulton and F.C. Tenover et al., 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med., 348: 1342-1347

Dryla, A., S. Prustomersky, D. Gelbmann, M. Hanner and E. Beetinger et al., 2005. Comparison of antibody repertoies against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin. Diagnostic. Lab. Immun., 12: 387-398

Etz, H., D.B. Min, T. Henics, A. Dryla and B. Winkler, et al., 2002. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Applied Biol. Sci., 99: 6573-6578

Foster, T.J., 1991. Potential for vaccination against infections caused by Staphylococcus aureus vaccine. Vaccine, 9: 221-227

Gales, A.C., S.S. Andrade, H.S. Sader and R.N. Jones, 2004. Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: Report from the SENTRY antimicrobial surveillance program. J. Chemother., 16: 323-328

Gill, S.R, D.E. Fouts, G.L. Archer, E.F. Mongodin and R.T. Deboy, et al., 2005. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin resistant Staphylococcus aureus strain and a biofilm-producing methicillin resistant Staphylococcus epidermidis strain. J. Bacteriol., 18: 2426-2438.

Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri and F.C. Tenover, 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother., 40: 135-136.

Josephson, E., O. Hartford, L. Obrien, J.M. Patti and T. Foster, 2001. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J. Infect. Dis., 184: 1572-1580

McKenney, D., K.L. Pouliot, Y. Wang, V. Murthy and M. Ulrich et al., 1999. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science, 284: 1523-1527

Muder, R.R., C. Brennen, M.M. Wagener, R.M. Vickers and J.D. Rihs et al., 1991. Methicillin-resistant staphylococcal colonization and infection in a long-term care facility. Ann. Intern. Med., 114: 107-112

Pourmand, M.R. and S. Foster, 2006. A novel bioinformatic approach for Staphylococcal vaccine development. Tehran Uni. Med. J., 64: 19-26

Rahman, M., W.C. Noble, B. Cookson, D. Baird and J. Coia, 1987. Mupirocin resistant Staphylococcus aureus. Lancet, 330: 387-388.

Schmitz, F.J., E. Lindenlauf, B. Hofmann, A.C. Fluit and J. Verhoef et al., 1998. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J. Antimicrob. Chemother., 42: 489-495.

Senna, J.P. and D.M. Roth, J.S. Oliveira, D.C. Machado and D.S. Santos, 2003. Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine approach. Vaccine, 21: 2661-2666

Shehata, A.I., 2008. Phylogenetic diversity of Staphylococcus aureus by random amplification of polymorphic DNA. Aust. J. Basic Applied Sci., 2: 858-863

Shinefield, H., S. Black, A. Fattom, G. Horwith and S. Rasgon et al., 2002. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med., 346: 491-496

Vytvytska, O., E. Nagy, M. Bluggel, H.E. Meyer, R. Kurzbauer, Huber and C.S. Klade, 2002. Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics, 2: 580-590

Walker, E.S., J.E. Vasquez, R. Dula, H. Bullock and F.A. Sarubbi, 2003. Mupirocin resistant, Methicillin-resistant Staphylococcus aureus: Does mupirocin remain effective? Infect. Control Hosp. Epidemiol., 24: 342-346

Yang, J.A., D.W. Park, J.W. Sohn, I.S. Yang, K.H. Kim and M.J. Kim, 2006. Molecular analysis of isoleucyl-tRNA synthetase mutations in clinical isolates of methicillin-resistant Staphylococcus aureus with low-level mupirocin resistance. J. Korean Med. Sci., 21: 827-832

 
 
 
Insight Knowledge © 2018